Mevoq partners with pharmaceutical teams to plan and execute regulatory strategies across FDA, EMA, Health Canada, and other global authorities. We help programs move forward with clarity, confidence, and regulatory foresight.
In an environment where every day of delay impacts patient access and commercial viability, reliance on generalist advice is a risk you cannot afford.
Strategic support tailored to the critical milestones of drug development and global regulatory submission.
Navigate complex regulatory pathways with confidence. We design optimal strategies for global market access.
Expertise BriefExpert preparation of submission-ready regulatory documents that meet global standards.
Expertise BriefBuild robust quality systems that pass inspections and ensure sustainable compliance.
Expertise BriefClear, compelling regulatory narratives that accelerate review and approval.
Expertise BriefProactive identification and mitigation of regulatory and quality risks.
Expertise BriefStreamline your compliance operations with expert administrative assistance.
Expertise BriefPrecision & Partnership
We embed directly with your scientific and clinical teams, translating complex data into compelling regulatory arguments that withstand agency scrutiny.
We assess your data package against current agency thinking to identify gaps early.
Detailed roadmap development for IND/CTA through to NDA/MAA filings.
Direct representation and meeting facilitation with FDA, EMA, and others.
Lifecycle management, labeling updates, and compliance auditing.
Perspectives from regulatory leaders who have partnered with Mevoq on complex submissions.
Mevoq cut our FDA submission timeline by 40%. Their expertise in regulatory strategy is unmatched. We launched 3 months ahead of schedule.
Analysis of evolving global regulatory landscapes by senior personnel.
Clinical holds can delay drug development by months or years. We analyze the most common triggers for FDA holds in the current regulatory climate and how to avoid them.
The FDA has recently updated its framework for gene therapy products, emphasizing long-term safety monitoring and manufacturing consistency. Here is what biotech sponsors need to know to prevent clinical holds.
Beyond tax credits, Orphan Drug Designation offers strategic advantages including seven years of market exclusivity. Here is how to construct a winning ODD application.
We operate with strict confidentiality. Schedule a primary assessment with a principal consultant to review your program.